Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tectonic Therapeutic (TECX) Accumulated Expenses (2017 - 2026)

Tectonic Therapeutic (TECX) has 10 years of Accumulated Expenses data on record, last reported at $9.0 million in Q1 2026.

  • On a quarterly basis, Accumulated Expenses rose 82.86% to $9.0 million in Q1 2026 year-over-year; TTM through Mar 2026 was $9.0 million, a 82.86% increase, with the full-year FY2025 number at $7.3 million, down 6.5% from a year prior.
  • Accumulated Expenses reached $9.0 million in Q1 2026 per TECX's latest filing, up from $7.3 million in the prior quarter.
  • Over the last five years, Accumulated Expenses for TECX hit a ceiling of $20.0 million in Q2 2024 and a floor of $1.1 million in Q1 2024.
  • A 5-year average of $8.6 million and a median of $7.8 million in 2024 define the central range for Accumulated Expenses.
  • Peak YoY movement for Accumulated Expenses: plummeted 82.34% in 2023, then surged 441.81% in 2024.
  • Tracing TECX's Accumulated Expenses over 5 years: stood at $11.7 million in 2022, then plummeted by 30.61% to $8.1 million in 2023, then decreased by 3.57% to $7.8 million in 2024, then decreased by 6.5% to $7.3 million in 2025, then grew by 22.25% to $9.0 million in 2026.
  • Business Quant data shows Accumulated Expenses for TECX at $9.0 million in Q1 2026, $7.3 million in Q4 2025, and $6.8 million in Q3 2025.